This is a small, routine sale by a director following an option exercise. No material signal for the stock. Monitor for any larger insider sales or changes in insider trading patterns.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $588.61entry
- T+1 · 6d ago +1.20%α −0.12% · $595.66
- T+4 · todayOpen
- T+5 · in 7h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Christopher Patusky filed a Form 144 notice of intent to sell 1,210 shares of United Therapeutics Corp common stock, valued at approximately $701,800 based on the filing. The shares were acquired through a stock option exercise on the same date. This is a routine insider sale by a director, representing a small fraction of the company's $24.1B market cap.
Key Facts
- Director Christopher Patusky filed Form 144 to sell 1,210 shares of United Therapeutics Corp common stock.
- The approximate market value of the proposed sale is $701,800.
- Shares were acquired via a stock option exercise on November 9, 2026.
- The sale is planned for execution on November 9, 2026, through Morgan Stanley Smith Barney LLC.
- The proposed sale represents about 0.003% of the company's $24.1B market cap.
Financial Impact
Proposed sale of 1,210 shares worth approximately $701,800, a de minimis amount relative to the company's $24.1B market cap.
Risk Factors
- Form 144 is an intent to sell; the actual sale may not occur.
- Insider sales can sometimes precede negative news, but the size here is negligible.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010885 |
| Document: 0001950047-26-010885-index.html | 0001950047-26-010885 |
| Document: 0001950047-26-010885.txt | 0001950047-26-010885 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $587.88 Now $587.88 +0.00% settles Nov 24
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Viewing Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers